Could Johnson & Johnson Be a Big Winner in the Flu Vaccine Market?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·3 min read

Johnson & Johnson (NYSE: JNJ) hasn't been a major player in the vaccine market in the past, but that's changing. It's now seeking to develop a flu vaccine through a recent deal with small biotech Cidara Therapeutics (NASDAQ: CDTX). In this Motley Fool Live video recorded on April 7, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J could become a big winner in the flu vaccine market.